ライフサイエンスコーパス: drug-resistant tuberculosis

1 rammatically incurable tuberculosis (totally drug-resistant tuberculosis).

2 ti-drug resistant tuberculosis and extremely drug resistant tuberculosis.

3 ens) has demonstrated activity against multi-drug-resistant tuberculosis.

4 tidrug-resistant tuberculosis or extensively drug-resistant tuberculosis.

5 ates for multidrug-resistant and extensively drug-resistant tuberculosis.

6 s) severely compromises treatment options of drug-resistant tuberculosis.

7 ies is being explored for drug-sensitive and drug-resistant tuberculosis.

8 demic of multidrug-resistant and extensively drug-resistant tuberculosis.

9 specifically to isoniazid, leading to multi-drug-resistant tuberculosis.

10 of this structure class for the treatment of drug-resistant tuberculosis.

11 eveloped as a therapy for drug-sensitive and drug-resistant tuberculosis.

12 d not on ART, and 1749 (15%) had extensively drug-resistant tuberculosis.

13 potential therapeutic utility against highly drug-resistant tuberculosis.

14 lish the efficacy of surgery in treatment of drug-resistant tuberculosis.

15 ude data on HIV/tuberculosis coinfection and drug-resistant tuberculosis.

16 resection is beneficial in the treatment of drug-resistant tuberculosis.

17 une-based therapies for adjunct treatment of drug-resistant tuberculosis.

18 s on the future burden of drug-sensitive and drug-resistant tuberculosis.

19 studies are warranted to define its role in drug-resistant tuberculosis.

20 le, we describe the current global status of drug-resistant tuberculosis.

21 n and incidence of both drug-susceptible and drug-resistant tuberculosis.

22 gimen appeared to lead to the development of drug-resistant tuberculosis.

23 thrust for new drugs to counteract multiple drug-resistant tuberculosis.

24 rstone of a new regimen for the treatment of drug-resistant tuberculosis.

25 ifloxacin, have revolutionized treatment for drug-resistant tuberculosis.

26 gence of multidrug-resistant and extensively drug-resistant tuberculosis.

27 ndicate Ar-A to be a promising drug lead for drug-resistant tuberculosis.

28 in improving current treatment regimens for drug-resistant tuberculosis.

29 ration recommended in 2019 US guidelines for drug-resistant tuberculosis.

30 sion of unsuspected or ineffectively treated drug-resistant tuberculosis.

31 ug-sensitive tuberculosis and 6-9 months for drug-resistant tuberculosis.

32 Carbapenems are recommended for treatment of drug-resistant tuberculosis.

33 with proven treatment-shortening efficacy in drug-resistant tuberculosis.

34 en hope for better and shorter treatments of drug-resistant tuberculosis.

35 eatment and prevent the development of multi-drug-resistant tuberculosis.

36 le participants, of whom 40% had extensively drug-resistant tuberculosis.

37 ezolid toxicity in patients with extensively drug-resistant tuberculosis.

38 mportant tool in diagnosis and management of drug-resistant tuberculosis.

39 near-patient technology to rapidly diagnose drug-resistant tuberculosis.

40 HIV patients with multidrug and extensively drug-resistant tuberculosis.

41 rease incidence of both drug-susceptible and drug-resistant tuberculosis.

42 1043 patients in the non-BFP group developed drug-resistant tuberculosis.

43 alth Organization to treat leprosy and multi-drug-resistant tuberculosis.

44 mmittee-supported programmatic management of drug-resistant tuberculosis.

45 osed a threat of transmission of extensively drug-resistant tuberculosis.

46 of action in order to tackle the scourge of drug-resistant tuberculosis.

47 ting many cases of multidrug and extensively drug-resistant tuberculosis.

48 ns-are likely crucial to the pathogenesis of drug-resistant tuberculosis.

49 is Commission, we examine several aspects of drug-resistant tuberculosis.

50 or, are being evaluated for the treatment of drug-resistant tuberculosis.

51 new therapeutic agents for the treatment of drug-resistant tuberculosis.

52 st distributions on the future prevalence of drug-resistant tuberculosis.

53 is study improves the chances of controlling drug-resistant tuberculosis.

54 tuation worldwide and the growing problem of drug-resistant tuberculosis.

55 and prevention of both drug-susceptible and drug-resistant tuberculosis.

56 treatment shortening of drug-susceptible and drug-resistant tuberculosis.

57 re a key determinant of the future burden of drug-resistant tuberculosis.

58 Following recent research advances for drug-resistant tuberculosis, a 6-month regimen containin

59 resulted in a 40% increase in prevalence of drug-resistant tuberculosis after 20 years.

60 eatments for paediatric drug-susceptible and drug-resistant tuberculosis, albeit generally effective,

61 However, little is known about the rates of drug-resistant tuberculosis among health care workers in

62 uropean Region has the highest proportion of drug-resistant tuberculosis among new and retreated case

63 population of new tuberculosis cases and of drug-resistant tuberculosis among new cases reported fro

64 the most recent years, notification rates of drug-resistant tuberculosis among new tuberculosis cases

65 time-series trends in notification rates of drug-resistant tuberculosis among new tuberculosis cases

66 together lead to high level resistance multi-drug resistant tuberculosis and extremely drug resistant

67 st multidrug-resistant (MDR) and extensively drug-resistant tuberculosis and an excellent pharmacolog

68 d isolates from 651 patients for extensively drug-resistant tuberculosis and developed regimens that

69 uences that are diagnostic of two pathogens (drug-resistant tuberculosis and Escherichia coli) by usi

70 0 to 130,000) is similar to the estimate for drug-resistant tuberculosis and for multiple myeloma.(,)

71 ese advances are insufficient in the face of drug-resistant tuberculosis and HIV co-infection.

72 ference standard leads to under-treatment of drug-resistant tuberculosis and increased mortality.

73 hical and medicolegal aspects of extensively drug-resistant tuberculosis and other resistant strains.

74 on for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-

75 s a high-yield intervention for detection of drug-resistant tuberculosis and prevention of ongoing tr

76 The rise of multidrug-resistant and totally drug-resistant tuberculosis and the association with an

77 c and treatment strategies for patients with drug-resistant tuberculosis and their contacts.

78 We describe the management of extensively drug-resistant tuberculosis and treatment outcomes among

79 lis, drug-susceptible tuberculosis, or multi-drug resistant tuberculosis), and to a GBD country; repo

80 , the potential widening of their use beyond drug-resistant tuberculosis, and lessons for utilising n

81 eatment and management of drug-sensitive and drug-resistant tuberculosis, and provide an update on ne

82 c screens for bactericidal compounds against drug-resistant tuberculosis are beginning to yield novel

83 trials to optimize combinations of drugs for drug-resistant tuberculosis are lacking.

84 sis infection among contacts of persons with drug-resistant tuberculosis are lacking.

85 New approaches to the treatment of multi drug-resistant tuberculosis are needed.

86 Several key new developments regarding drug-resistant tuberculosis are outlined in this Commiss

87 tcomes with available treatment regimens for drug-resistant tuberculosis are poor.

88 ts while maintaining efficacy against highly drug-resistant tuberculosis are unclear.

89 ical, and genomic data from patient cases of drug-resistant tuberculosis backed by shareable, physica

90 so contribute substantially to the burden of drug-resistant tuberculosis because of their much higher

91 reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of advers

92 Extensively drug-resistant tuberculosis can be cured in HIV-negative

93 umber of multidrug resistant and extensively drug resistant tuberculosis cases continues to rise.

94 tuberculosis incidence and more than 90% of drug-resistant tuberculosis cases emerging in the region

95 mplemented, and the actual numbers of global drug-resistant tuberculosis cases have yet to be estimat

96 The treatment of drug-resistant tuberculosis cases is challenging, as dru

97 To estimate the relative fitness of drug-resistant tuberculosis cases, we compared the incid

98 Among South Africans treated for drug-resistant tuberculosis, CYP3A5*3 was associated wit

99 id, comprehensive DST approach could enhance drug-resistant tuberculosis diagnosis and treatment, ult

100 (DLM) in treatment regimen for patients with drug-resistant tuberculosis (DR-TB) and limited therapeu

101 (DLM) in treatment regimen for patients with drug-resistant tuberculosis (DR-TB) and limited therapeu

102 In generalized drug-resistant tuberculosis (DR-TB) HIV epidemics, ident

103 In generalized drug-resistant tuberculosis (DR-TB) human immunodeficien

104 (HIV)-infected patients and the emergence of drug-resistant tuberculosis (DR-TB) is a growing problem

105 Increasingly complex drug-resistant tuberculosis (DR-TB) is a major global he

106 The management of children with drug-resistant tuberculosis (DR-TB) is challenging, and

107 Bedaquiline is a critical component of new drug-resistant tuberculosis (DR-TB) treatment regimens.

108 Individuals treated for drug-resistant tuberculosis (DR-TB) with aminoglycosides

109 eat individuals presumed to be infected with drug-resistant tuberculosis (DR-TB).

110 ent sputum samples for clinical diagnosis of drug-resistant tuberculosis (DR-TB).

111 e-based second-line regimen for treatment of drug-resistant tuberculosis (DR-TB).

112 s new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB).

113 atment of multidrug-resistant or extensively drug-resistant tuberculosis (DR-tuberculosis) is challen

114 little evidence of patient acceptability for drug-resistant tuberculosis (DRTB) care in the context o

115 ns to undermine advances in the treatment of drug-resistant tuberculosis (DRTB).

116 In this study, drug-resistant tuberculosis drug regimens, including bed

117 ST) is essential for diagnosing and treating drug-resistant tuberculosis effectively, and next-genera

118 ic activity, has the country response to the drug-resistant tuberculosis epidemic been so ineffectual

119 ere associated with more severe epidemics of drug-resistant tuberculosis, fitness distributions with

120 ve led WHO to recommend all-oral therapy for drug-resistant tuberculosis for the first time ever in 2

121 made in prevention and care of patients with drug-resistant tuberculosis, further decline of the tube

122 The patients with extensively drug-resistant tuberculosis had undergone more treatment

123 However, concern about drug-resistant tuberculosis has been eclipsed by that of

124 idrug-resistant tuberculosis and extensively drug-resistant tuberculosis has been noted, particularly

125 Extensively drug-resistant tuberculosis has been reported in 45 coun

126 The recent rise of drug-resistant tuberculosis has complicated the choice o

127 The emergence of drug-resistant tuberculosis has created an urgent need f

128 ve improved with antiretroviral therapy, but drug-resistant tuberculosis has emerged as a major cause

129 tudies of explanted lungs from patients with drug-resistant tuberculosis have shown substantial drug-

130 treatment, the patient developed extensively drug-resistant tuberculosis, highlighting the importance

131 The increasing prevalence of drug-resistant tuberculosis highlights the need for iden

132 iline treatment in multidrug and extensively drug-resistant tuberculosis HIV might be compromised by

133 e is a key component of new WHO regimens for drug-resistant tuberculosis; however, predicting bedaqui

134 en eclipsed by that of totally and extremely drug-resistant tuberculosis--ie, resistance to all or ne

135 rts suggested the emergence of high rates of drug resistant tuberculosis in Egypt.

136 tiative supported programmatic management of drug-resistant tuberculosis in 90 countries.

137 ining the transmissibility and prevalence of drug-resistant tuberculosis in a population were investi

138 s infections among patients at high risk for drug-resistant tuberculosis in Botswana.

139 osis in children; detection and treatment of drug-resistant tuberculosis in children; and a more effe

140 ould enable early detection and treatment of drug-resistant tuberculosis in clinical settings.

141 lex isolates were collected from adults with drug-resistant tuberculosis in five high-endemic tubercu

142 ormation required to improve the outcomes of drug-resistant tuberculosis in high-burden settings.

143 examine the relationship of HIV infection to drug-resistant tuberculosis in other selected regions of

144 y virus (HIV) coepidemic and rising rates of drug-resistant tuberculosis in parts of the world add fu

145 fazimine in a cohort of patients treated for drug-resistant tuberculosis in South Africa.

146 ribution of recent transmission to spread of drug-resistant tuberculosis in Texas, we performed IS611

147 o evidence for the extensive transmission of drug-resistant tuberculosis in Texas.

148 n informed approach to the classification of drug-resistant tuberculosis in the era of new drugs.

149 t, and outcomes of patients with extensively drug-resistant tuberculosis in Tomsk, Russia.

150 Factors associated with multi-drug-resistant tuberculosis included a history of previo

151 sonalized rather than empirical treatment of drug-resistant tuberculosis, including the use of antimi

152 infection was shown to be a risk factor for drug-resistant tuberculosis, independent of geographic l

153 ographical regions with a high prevalence of drug-resistant tuberculosis (India, Moldova, the Philipp

154 eriment 1, before treatment, 5 patients with drug-resistant tuberculosis infected 24 of 90 guinea pig

155 eriment 2, before treatment, 9 patients with drug-resistant tuberculosis infected 40 of 90 guinea pig

156 The upsurge of drug resistant tuberculosis is major health threat globa

157 Extensively drug-resistant tuberculosis is a burgeoning global healt

158 Prevention of drug-resistant tuberculosis is a global health priority.

159 Drug-resistant tuberculosis is a growing public health t

160 s remains a major global health problem, and drug-resistant tuberculosis is a growing threat.

161 zinamide, the injectables, and isoniazid for drug-resistant tuberculosis is a high priority.

162 Drug-resistant tuberculosis is a major public health con

163 The emergence of drug-resistant tuberculosis is challenging tuberculosis

164 Treatment of drug-resistant tuberculosis is hindered by the high toxi

165 and duration of drugs with activity against drug-resistant tuberculosis is paramount.

166 treatment to stop person-to-person spread of drug-resistant tuberculosis is uncertain.

167 anid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Le

168 etting where there is no ongoing outbreak of drug-resistant tuberculosis, isoniazid-resistant tubercu

169 for rapidly detecting multidrug-/extensively drug-resistant tuberculosis (M/XDR TB), but large studie

170 Emergence of drug-resistant tuberculosis makes the discovery of new t

171 s in these patients suggest that extensively drug-resistant tuberculosis may be acquired through prev

172 oor treatment outcomes associated with multi-drug resistant tuberculosis (MDR-TB) are of major concer

173 The emergence of multi- and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respecti

174 Multi-drug-resistant tuberculosis (MDR-TB) is an increasing pu

175 Multi-drug-resistant tuberculosis (MDR-TB) is simultaneously r

176 ncluding multidrug-resistant and extensively drug-resistant tuberculosis, might become less relevant.

177 should expand the capacity for detection of drug-resistant tuberculosis near the point of care.

178 Most drug-resistant tuberculosis occurs due to transmission o

179 Far more drug-resistant tuberculosis occurs in children than is d

180 ed by WHO, have transformed the treatment of drug-resistant tuberculosis, offering safer and more eff

181 ome (cure, dropout, death, or development of drug-resistant tuberculosis or treatment failure) was re

182 273 South African patients with extensively drug-resistant tuberculosis, or resistance beyond extens

183 in the USA highlights the risks of acquiring drug-resistant tuberculosis overseas, and the unique cha

184 Household contact investigation around drug-resistant tuberculosis patients is a high-yield int

185 Drug-resistant tuberculosis persists as a major public h

186 DR) tuberculosis, and more recently, totally drug-resistant tuberculosis pose a threat to global tube

187 resistant (MDR) tuberculosis and extensively drug-resistant tuberculosis poses a major threat to glob

188 Patients with extensively drug-resistant tuberculosis received daily, supervised t

189 xperiment 1, patients initiated an optimized drug-resistant tuberculosis regimen including bedaquilin

190 tion-defined group 1, 2, and 4 drugs used in drug-resistant tuberculosis regimens to inform clinical

191 Drug-resistant tuberculosis represents a global emergenc

192 In some countries such as South Africa, drug-resistant tuberculosis represents less than 3% of a

193 data suggest that control of the epidemic of drug-resistant tuberculosis requires an increased focus

194 Bedaquiline, a potent new therapy for drug-resistant tuberculosis, results in improved surviva

195 at interventions to prevent the emergence of drug-resistant tuberculosis should target bacterial as w

196 Notification rates of drug-resistant tuberculosis showed diverse trends, with

197 ield of such investigations in households of drug-resistant tuberculosis source cases is unknown.

198 uartile range, 21-302) household contacts of drug-resistant tuberculosis source cases.

199 s in 240 multidrug-resistant and extensively drug-resistant tuberculosis strains and quantified their

200 ant tuberculosis and over 90% of extensively drug-resistant tuberculosis strains are also PZA resista

201 e analysed MTBC isolates from the nationwide drug-resistant tuberculosis surveillance with 70 countie

202 The resurgence of drug resistant tuberculosis (TB) is a significant global

203 Household contacts of patients with drug-resistant tuberculosis (TB) are at high risk for be

204 r AMR pathogens, both historical and ongoing drug-resistant tuberculosis (TB) epidemics are character

205 Drug-resistant tuberculosis (TB) is emerging as a major

206 rate, comprehensive, and timely detection of drug-resistant tuberculosis (TB) is essential to inform

207 Drug-resistant tuberculosis (TB) is estimated to cause 1

208 lity risk and improve treatment outcomes for drug-resistant tuberculosis (TB) patients, including ind

209 Drug-resistant tuberculosis (TB) poses a significant pub

210 The increasing burden of drug-resistant tuberculosis (TB) poses an escalating thr

211 Drug-resistant tuberculosis (TB) presents a major challe

212 Patterns of transmission of drug-resistant tuberculosis (TB) remain poorly understoo

213 Effectively responding to drug-resistant tuberculosis (TB) requires accurate and t

214 A burgeoning epidemic of drug-resistant tuberculosis (TB) threatens to derail glo

215 In view of emerging drug-resistant tuberculosis (TB), host-directed adjunct

216 Drug-resistant tuberculosis (TB), one of the leading cau

217 ta for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), the American Thoracic

218 uberculosis groups could affect epidemics of drug-resistant tuberculosis (TB).

219 re urgently needed to overcome the threat of drug-resistant tuberculosis (TB).

220 ing (DST) to design appropriate regimens for drug-resistant tuberculosis (TB).

221 in South Africa have undiagnosed active and drug-resistant tuberculosis (TB).

222 ontaining regimens are highly active against drug-resistant tuberculosis, the contribution of clofazi

223 1 patients tested, 48 (7.4%) had extensively drug-resistant tuberculosis; the remaining 603 patients

224 tted from 2003 to 2008 for the initiation of drug-resistant tuberculosis therapy.

225 lamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed inte

226 Drug-resistant tuberculosis threatens recent gains in th

227 We non-randomly assigned 26 patients with drug-resistant tuberculosis to the DRMPa200Z regimen.

228 line, 1200-mg linezolid, and pretomanid), on drug-resistant tuberculosis transmission, using the huma

229 ose linezolid for 72 hours, did not decrease drug-resistant tuberculosis transmission.

230 pril 1994, a passenger with infectious multi-drug resistant tuberculosis traveled on commercial-airli

231 of a bedaquiline-containing regimen from 12 drug-resistant tuberculosis treatment facilities in Cape

232 rtant component of both drug-susceptible and drug-resistant tuberculosis treatment regimens.

233 ents with multidrug-resistant or extensively drug-resistant tuberculosis undergoing treatment is poor

234 he Lancet Respiratory Medicine Commission on drug-resistant tuberculosis was published in 2017, which

235 None of the patients with extensively drug-resistant tuberculosis were coinfected with the hum

236 The largest number of cases of drug-resistant tuberculosis were reported in counties bo

237 The WHO guidelines on treating drug-resistant tuberculosis were updated in 2019 with a

238 berculosis, or resistance beyond extensively drug-resistant tuberculosis, were followed up over a per

239 nts with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often lim

240 erculosis treatment and manage patients with drug-resistant tuberculosis who are infected with HIV ar

241 Retrospective study of patients with drug-resistant tuberculosis who were admitted from 2003

242 gnosis of 20 downstream cases of extensively drug-resistant tuberculosis with almost identical sequen

243 Treatment of drug-resistant tuberculosis with bedaquiline-pretomanid-

244 We undertook enhanced surveillance for drug-resistant tuberculosis with sputum culture and drug

245 ogists from countries with a heavy burden of drug-resistant tuberculosis working with data scientists

246 SLDs) is a problem in treating patients with drug-resistant tuberculosis worldwide.

247 the prevalence of the MDR-TB and extensively drug resistant tuberculosis (XDR-TB) cases, there is an

248 istant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) (M/XDR-TB).

249 ansmission has been described in extensively drug-resistant tuberculosis (XDR-TB) and HIV co-infected

250 Patients with extensively drug-resistant tuberculosis (XDR-TB) are also resistant

251 Worldwide emergence of extensively drug-resistant tuberculosis (XDR-TB) has raised global p

252 culosis (MDR-TB) and over 90% of extensively drug-resistant tuberculosis (XDR-TB) strains are also PZ

253 Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB w

254 culosis (Mtb) have given rise to extensively drug-resistant tuberculosis (XDR-TB).

255 Extensively drug-resistant tuberculosis (XDR-tuberculosis) is a glob